HIMS falls after FDA GLP-1 drug warning overshadows Australia expansion
Hims & Hers Health shares began September in the red as an FDA warning about unapproved GLP-1 weight-loss drugs drew focus. The stock fell 4% to close at $28.44 on Tuesday.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.